JP2016510316A - 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤 - Google Patents

白血病の治療に使用するためのｄｏｔ１ｌ阻害剤 Download PDF

Info

Publication number
JP2016510316A
JP2016510316A JP2015549801A JP2015549801A JP2016510316A JP 2016510316 A JP2016510316 A JP 2016510316A JP 2015549801 A JP2015549801 A JP 2015549801A JP 2015549801 A JP2015549801 A JP 2015549801A JP 2016510316 A JP2016510316 A JP 2016510316A
Authority
JP
Japan
Prior art keywords
compound
cancer
alkyl
subject
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015549801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510316A5 (cg-RX-API-DMAC7.html
Inventor
エム．ポロック ロイ
エム．ポロック ロイ
アール． ダイグル スコット
アール． ダイグル スコット
Original Assignee
エピザイム，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピザイム，インコーポレイティド filed Critical エピザイム，インコーポレイティド
Publication of JP2016510316A publication Critical patent/JP2016510316A/ja
Publication of JP2016510316A5 publication Critical patent/JP2016510316A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2015549801A 2012-12-21 2013-12-20 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤 Pending JP2016510316A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745294P 2012-12-21 2012-12-21
US61/745,294 2012-12-21
PCT/US2013/077082 WO2014100662A1 (en) 2012-12-21 2013-12-20 Dot1 l inhibitors for use in the treatment of leukemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018192426A Division JP2019031525A (ja) 2012-12-21 2018-10-11 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤

Publications (2)

Publication Number Publication Date
JP2016510316A true JP2016510316A (ja) 2016-04-07
JP2016510316A5 JP2016510316A5 (cg-RX-API-DMAC7.html) 2017-02-02

Family

ID=49956460

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015549801A Pending JP2016510316A (ja) 2012-12-21 2013-12-20 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤
JP2018192426A Pending JP2019031525A (ja) 2012-12-21 2018-10-11 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018192426A Pending JP2019031525A (ja) 2012-12-21 2018-10-11 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤

Country Status (6)

Country Link
US (2) US20150342979A1 (cg-RX-API-DMAC7.html)
EP (1) EP2934550A1 (cg-RX-API-DMAC7.html)
JP (2) JP2016510316A (cg-RX-API-DMAC7.html)
AU (1) AU2013361076B2 (cg-RX-API-DMAC7.html)
CA (1) CA2894220A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014100662A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882750A4 (en) 2012-08-10 2016-08-17 Epizyme Inc INHIBITORS OF THE PROTEIN METHYLTRANSFERASE DOT1L AND METHOD OF USE THEREOF
US9597348B2 (en) 2012-09-06 2017-03-21 Epizyme, Inc. Method of treating leukemia
US9446064B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. Combination therapy for treating cancer
AU2014239520A1 (en) 2013-03-15 2015-09-10 Epizyme, Inc. Methods of synthesizing substituted purine compounds
US20170166976A1 (en) * 2014-07-18 2017-06-15 The Regents Of The University Of Colorado, A Body Corporate Dot1l inhibition in patients with mn1-high aml
WO2016023017A1 (en) * 2014-08-08 2016-02-11 Baylor College Of Medicine Dot1l inhibitors and uses thereof
WO2016029127A1 (en) * 2014-08-22 2016-02-25 The Regents Of The University Of Colorado, A Body Corporate Dot1l inhibitors and uses thereof
CA2960287A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Injectable formulations for treating cancer
WO2016051396A1 (en) * 2014-09-30 2016-04-07 Susan Eve Vecht-Lifshitz Pharmaceutical compositions for treating ebola virus disease
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
US10869868B2 (en) 2016-01-26 2020-12-22 Memorial Sloan Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
GB201901817D0 (en) 2019-02-11 2019-04-03 Phoremost Ltd Methods
CN110092804A (zh) * 2019-03-29 2019-08-06 广州盈升生物科技有限公司 一种含双环基团的嘌呤化合物及其制备方法
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008041767A1 (en) * 2006-10-05 2008-04-10 Banyu Pharmaceutical Co., Ltd. Gene/protein marker for prediction or diagnosis of pharmacological efficacy of aurora a inhibitor
JP2008295444A (ja) * 2006-10-11 2008-12-11 Astellas Pharma Inc Ｅｍｌ４−ａｌｋ融合遺伝子
JP2010046057A (ja) * 2008-07-22 2010-03-04 Akita Univ 癌細胞の治療感受性増強剤、癌細胞の治療感受性の判定方法、および癌細胞の治療感受性判定キット
US20120142625A1 (en) * 2010-12-03 2012-06-07 Epizyme, Inc. Substituted Purine And 7-Deazapurine Compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597348B2 (en) * 2012-09-06 2017-03-21 Epizyme, Inc. Method of treating leukemia
US9446064B2 (en) * 2013-03-14 2016-09-20 Epizyme, Inc. Combination therapy for treating cancer
US10143704B2 (en) * 2013-11-13 2018-12-04 Epizyme, Inc. Methods for treating cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008041767A1 (en) * 2006-10-05 2008-04-10 Banyu Pharmaceutical Co., Ltd. Gene/protein marker for prediction or diagnosis of pharmacological efficacy of aurora a inhibitor
JP2008295444A (ja) * 2006-10-11 2008-12-11 Astellas Pharma Inc Ｅｍｌ４−ａｌｋ融合遺伝子
JP2010046057A (ja) * 2008-07-22 2010-03-04 Akita Univ 癌細胞の治療感受性増強剤、癌細胞の治療感受性の判定方法、および癌細胞の治療感受性判定キット
US20120142625A1 (en) * 2010-12-03 2012-06-07 Epizyme, Inc. Substituted Purine And 7-Deazapurine Compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BASAVAPATHRUNI,A. ET AL.: "Conformational adaptation drives potent, selective and durable inhibition of the human protein methy", CHEM. BIOL. DRUG. DES., vol. 80, no. 6, JPN5016001262, 9 October 2012 (2012-10-09), pages 971 - 80, XP072378549, ISSN: 0003643309, DOI: 10.1111/cbdd.12050 *
DAIGLE,S.R. ET AL: "Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.", CANCER CELL, vol. 20, no. 1, JPN5016001260, 12 July 2011 (2011-07-12), US, pages 53 - 65, XP028379881, ISSN: 0003643308, DOI: 10.1016/j.ccr.2011.06.009 *

Also Published As

Publication number Publication date
AU2013361076B2 (en) 2018-08-30
US20150342979A1 (en) 2015-12-03
CA2894220A1 (en) 2014-06-26
US20200113923A1 (en) 2020-04-16
JP2019031525A (ja) 2019-02-28
WO2014100662A1 (en) 2014-06-26
EP2934550A1 (en) 2015-10-28

Similar Documents

Publication Publication Date Title
JP2019031525A (ja) 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤
AU2013361076A1 (en) DOT1 L inhibitors for use in the treatment of leukemia
JP5931905B2 (ja) 置換プリン及び７‐デアザプリン化合物
US11786533B2 (en) Use of EZH2 inhibitors for treating cancer
US20200330472A1 (en) Method of treating cancer
US20200016162A1 (en) Inhibitors of human ezh2, and methods of use thereof
US11753433B2 (en) Methods of synthesizing substituted purine compounds
JP2018062535A (ja) ガンの治療方法
US20190038633A1 (en) Methods of treating cancer
JP2016517434A (ja) 癌を処置するための併用療法
EP3022195A2 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
US10143704B2 (en) Methods for treating cancer
WO2018223030A1 (en) Use of ezh2 inhibitors for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170919

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170922

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180316

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180612